<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5959">
  <stage>Registered</stage>
  <submitdate>25/01/2016</submitdate>
  <approvaldate>25/01/2016</approvaldate>
  <nctid>NCT02688101</nctid>
  <trial_identification>
    <studytitle>Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors</studytitle>
    <scientifictitle>A Phase 1 Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CMD-2015-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neoplasms</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - DpC

Experimental: DpC - DpC capsules, administered orally


Treatment: drugs: DpC
iron chelator

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Recommended phase 2 dose as determined by number of participants at each dose level with dose limiting toxicities - Determine recommended phase 2 dose</outcome>
      <timepoint>36 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum DpC plasma concentration [Cmax] following dosing on Days 1 and 28 based on blood draws taken at 1, 2, 4, 8, and 24 hours after dosing - Maximum DpC plasma concentration</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the DpC plasma concentration vs. time curve [AUC] following dosing on Days 1 and 28 based on blood draws taken at 1, 2, 4, 8, and 24 hours after dosing - DpC area under the plasma concentration vs. time curve</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients with tumor responses as assessed by RECIST criteria - number of tumor responses by RECIST criteria</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Signed informed consent prior to initiation of any study-specific procedures;

          -  Histologically or cytologically confirmed diagnosis of an advanced or metastatic solid
             tumor for which standard therapy either does not exist or has proven ineffective,
             intolerable, or unacceptable for the patient;

          -  At least one measurable lesion as defined by RECIST v1.1, except for patients with
             castrate resistant prostate cancer, who may be enrolled with objective evidence of
             disease per PCWG2 criteria, and patients with ovarian cancer who may be enrolled
             without measurable disease but who are evaluable by CA125 per GCIC criteria;

          -  life expectancy at least 3 months;

          -  ECOG performance status 0-1;

          -  Adequate bone marrow reserve, cardiac, renal and liver function, defined by

          -  absolute neutrophil count at least 1.5 x 10(9)/L;

          -  platelet count at least 100 x 10(9)/L;

          -  hemoglobin at least 9 g/dL;

          -  ferritin at least 50 ug/L;

          -  ECHO shows ejection fraction at least 50% and no evidence of cardiac dysfunction;

          -  creatinine clearance &gt;50 mL/min (Cockcroft &amp; Gault formula);

          -  AST/ALT no more than 3 x ULN (5 x ULN if liver or bone involvement);

          -  serum albumin at least 28 g/L;

          -  INR no more than 1.5 x ULN;

          -  At least 3 weeks since chemotherapy, immunotherapy, hormone therapy, r other
             anticancer therapy or surgical intervention or at least 3 half-lie for monoclonal
             antibodies;

          -  Patients with castrate-resistant prostate cancer must maintain ongoing androgen
             deprivation therapy to provide serum testosterone &lt;50 mg/dL;

          -  Patients receiving bisphosphonate or denosumab therapy must be on stable doses for at
             least 4 weeks before initiating study treatment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inability to swallow oral medications or presence of a GI disorder deemed to
             jeopardize intestinal absorption of DpC;

          -  Persistent grade &gt;1 clinically significant toxicities related to prior anticancer
             treatment (except alopecia);

          -  Known primary CNS malignancy or CNS involvement (except for brain mets that have been
             treated and are stable and patient is off steroids);

          -  History of prior to concomitant malignancies (other than fully excised non-melanoma
             skin cancer, cured in situ cervical carcinoma, early stage bladder cancer or DCIS of
             breast) within 3 years of study entry;

          -  History of atrial fibrillation or evidence of atrial enlargement on baseline ECHO;

          -  History of hemoglobinopathy;

          -  Current use of iron chelation therapy;

          -  Other serious illness or medial condition;

          -  Participation in another clinical trial or treatment with any investigational drug
             within 30 days prior to study entry;

          -  Current use of anticoagulants at therapeutic levels;

          -  Pregnant or breast-feeding patients and men and women of child-bearing potential not
             using effective contraception while on study treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Lifehouse Cancer Treatment Centre - Sydney</hospital>
    <hospital>Olivia Newton John Cancer Centre - Heidelberg</hospital>
    <hospital>Monash Cancer Center - Melbourne</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <postcode> - Sydney</postcode>
    <postcode> - Heidelberg</postcode>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Collaborative Medicinal Development Pty Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Multicenter, open-label, dose-escalation and pharmacokinetic study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02688101</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Linda Mileshkin, MD</name>
      <address>Peter MacCallum Cancer Centre, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Kay Noel, PhD</name>
      <address />
      <phone>+1 510 525 4250</phone>
      <fax />
      <email>kay.noel@gmail.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>